Research programme: inflammation therapy - AmgenAlternative Names: Inflammation therapy research programme - Amgen
Latest Information Update: 14 Aug 2001
At a glance
- Originator Amgen
- Mechanism of Action Protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 14 Aug 2001 No-Development-Reported for Inflammation in USA (PO)
- 07 Feb 2001 Kinetix Pharmaceuticals has been acquired by Amgen
- 16 Nov 1998 New profile